Kenvue Inc. (KVUE)
| Market Cap | 35.86B +15.2% |
| Revenue (ttm) | 15.41B +1.8% |
| Net Income | 1.66B +16.9% |
| EPS | 0.85 +14.9% |
| Shares Out | 1.92B |
| PE Ratio | 21.96 |
| Forward PE | 15.43 |
| Dividend | $0.84 (4.50%) |
| Ex-Dividend Date | Sep 21, 2026 |
| Volume | 26,387,341 |
| Open | 18.38 |
| Previous Close | 18.01 |
| Day's Range | 18.38 - 18.77 |
| 52-Week Range | 14.02 - 20.13 |
| Beta | 0.45 |
| Analysts | Hold |
| Price Target | 19.50 (+4.45%) |
| Est. Earnings | Nov 2, 2026 |
About KVUE
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral a... [Read more]
Financial Performance
In 2025, Kenvue's revenue was $15.12 billion, a decrease of -2.14% compared to the previous year's $15.46 billion. Earnings were $1.47 billion, an increase of 42.72%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for KVUE stock is "Hold." The 12-month stock price target is $19.5, which is an increase of 4.45% from the latest price.
News
Kimberly-Clark, Kenvue Win Conditional EU Approval for $40 Billion Tie-Up
The European Commission—the EU's executive arm—said that the sale fully addresses officials' earlier concerns that the deal could hinder competition in tampon markets in Czechia, Estonia, and Slovakia...
EC approves Kimberly-Clark acquisition of Kenvue, subject to conditions
The European Commission has approved, under the EU Merger Regulation, the proposed acquisition by Kimberly-Clark (KMB) of Kenvue (KVUE), the commission announced. The approval is conditional upon full...
Kimberly-Clark Announces Successful Consent Solicitations for Kenvue Notes and Amendment to Terms of Exchange Offers
DALLAS, Oct. 13, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today that the requisite number of consents have been received to adopt certain proposed ame...
Kimberly-Clark announces planned executive transitions
Kimberly-Clark (KMB) announced planned executive transitions and updates to the future leadership team for the company upon completion of its pending acquisition of Kenvue (KVUE), which is expected in...
Kimberly-Clark Announces Planned Executive Transitions and Updates to Post-Closing Leadership Team
Russ Torres to Depart Kimberly-Clark for External CEO Role Carlos De Jesus to be Appointed as President, North America and Leonardo Curado to be Appointed as President, EMEA After Kenvue Acquisition D...
Kimberly-Clark Corporation Announces Commencement of Exchange Offers and Consent Solicitations for Kenvue Notes
DALLAS, Sept. 28, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today the commencement, in connection with its previously announced pending acquisition ("A...
Burning a Hole in My Pocket
I'm talking about the cash I have sitting here that I desperately want to get into the market. Earlier this year, I got a chunk of money from selling a house.
Kimberly-Clark offers remedies in bid for EU approval of Kenvue deal
Kimberly-Clark has offered concessions to address EU antitrust concerns about its $40 billion bid for Tylenol maker Kenvue , a filing on the European Commission website showed on Wednesday.
Kimberly-Clark readying asset sales for Kenvue deal EU approval, Reuters says
Kimberly-Clark (KMB) is preparing concessions to address EU antitrust concerns over its roughly $40B acquisition of Kenvue (KVUE), potentially clearing the way for regulatory approval after the Europe...
Kimberly-Clark readies EU remedies in bid for Kenvue deal, sources say
Kimberly-Clark is readying concessions to address EU antitrust concerns about its bid for Tylenol maker Kenvue that could help it win approval for the $40 billion deal after a preliminary review,...
My Favorite Consumer Staples Play Right Now
Owning consumer staples stocks is an absolute must in a dividend investing strategy. Most people turn to dividend stocks for two reasons — to generate income or to put the magic of compounding to work...
Kenvue Declares Quarterly Cash Dividend
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock. The quarterly dividend is paya...
Tylenol use in pregnancy may be linked with uterus, ovary changes in daughters
Female reproductive organ development may be impacted by a mother's use of Tylenol during pregnancy, according to researchers who emphasize that their study does not prove the pain medicine is to bl...
Australia clears Kimberly-Clark's acquisition of Kenvue but requires Carefree, Stayfree divestment
Australia's competition regulator on Wednesday approved Kimberly-Clark's proposed $40 billion takeover of Kenvue , on condition the company divests Kenvue's Carefree and Stayfree period care brands ...
Kimberly-Clark seeking EU approval for $40B Kenvue takeover, Reuters reports
Kimberly-Clark (KMB) has asked EU regulators permission for its proposed $40B takeover of Kenvue (KVUE), Reuters’ Bart Meijer reports. Kimberly-Clark announced the takeover in November 2025, and the d...
Kimberly-Clark seeks EU approval for $40 billion Kenvue deal
Kimberly-Clark has asked EU regulators permission for its proposed $40 billion takeover of Tylenol maker Kenvue, documents on the EU Commission's website showed.
Kimberly-Clark Appoints Suzana Blades as Senior Vice President and General Counsel
Accomplished legal executive and global litigator brings proven track record of enterprise risk management and strategic leadership to support Kimberly-Clark's next chapter of growth DALLAS, Aug. 13, ...
Kenvue price target lowered to $19 from $20 at UBS
UBS analyst Peter Grom lowered the firm’s price target on Kenvue (KVUE) to $19 from $20 and keeps a Neutral rating on the shares. The firm updated its model post…
Kenvue Quarterly report: Q2 2026
Kenvue has published its Q2 2026 quarterly earnings report on August 6, 2026.
Kenvue Earnings release: Q2 2026
Kenvue released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Kenvue misses quarterly estimates as inflation, tariffs squeeze margins
Kenvue narrowly missed Wall Street estimates for second-quarter results on Thursday as inflation, tariffs and currency-related costs squeezed margins.
Kenvue Posts Higher Profit, Sales as Turnaround Continues
Kenvue reported higher profit and sales in the second quarter, boosted by higher prices and volumes, as the company continues working to turn around its business ahead of its acquisition by Kimberly-C...
Kenvue reports Q2 adjusted EPS 31c, consensus 32c
Reports Q2 revenue $3.96B, consensus $3.97B. “We delivered our third consecutive quarter of net and organic sales growth, with broad-based gains across every segment and region,” said Kirk Perry, Chie...
Kenvue Reports Second Quarter 2026 Results
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the fiscal second quarter ended June 28, 2026. “We delivered our third consecutive quarter of net and orga...
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US
A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars o...